Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 2
2019 2
2020 3
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia.
Kulkarni U, Arunachalam AK, Palani HK, Nair RR, Balasundaram N, Venkatraman A, Korula A, Selvarajan S, Lionel S, Balasubramanian P, Maddali M, Abraham A, George B, Mathews V. Kulkarni U, et al. Among authors: balasundaram n. Cell Transplant. 2023 Jan-Dec;32:9636897231198178. doi: 10.1177/09636897231198178. Cell Transplant. 2023. PMID: 37706453 Free PMC article.
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N, Ganesan S, Chendamarai E, Palani HK, Venkatraman A, Alex AA, David S, Kumar SP, Radhakrishnan NR, Yasar M, Krishna S, Korula A, Kulkarni U, Janet NB, Balasubramanian P, Mathews V. Balasundaram N, et al. Blood Adv. 2022 Jan 25;6(2):652-663. doi: 10.1182/bloodadvances.2021005300. Blood Adv. 2022. PMID: 34625794 Free PMC article.
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
Kulkarni UP, Selvarajan S, Lionel S, Prakash MA, Palani HK, Balasundaram N, Venkataraman A, Korula A, Devasia AJ, Fouzia NA, Janet NB, Nair SC, Abraham A, Mani T, Lakshmanan J, Arunachalam AK, Balasubramanian P, George B, Mathews V. Kulkarni UP, et al. Among authors: balasundaram n. Blood Cancer J. 2022 Jan 31;12(1):22. doi: 10.1038/s41408-022-00619-3. Blood Cancer J. 2022. PMID: 35102152 Free PMC article. No abstract available.
Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia.
Palani HK, Ganesan S, Balasundaram N, Venkatraman A, Kulkarni U, Korula A, Nair SC, Mani T, Balasubramanian P, Abraham A, Puttamallesh VN, Gowda H, Mathews V. Palani HK, et al. Among authors: balasundaram n. Ann Hematol. 2024 Mar 1. doi: 10.1007/s00277-024-05673-4. Online ahead of print. Ann Hematol. 2024. PMID: 38427058 No abstract available.
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
Fouzia NA, Sharma V, Ganesan S, Palani HK, Balasundaram N, David S, Kulkarni UP, Korula A, Devasia AJ, Nair SC, Janet NB, Abraham A, Mani T, Lakshmanan J, Balasubramanian P, George B, Mathews V. Fouzia NA, et al. Among authors: balasundaram n. Br J Haematol. 2021 Jan;192(2):292-299. doi: 10.1111/bjh.17221. Epub 2020 Nov 20. Br J Haematol. 2021. PMID: 33216980 Free PMC article.
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide.
Kulkarni U, Ganesan S, Alex AA, Palani H, David S, Balasundaram N, Venkatraman A, Thenmozhi M, Jeyaseelan L, Korula A, Devasia A, Abraham A, Janet NB, Balasubramanian P, George B, Mathews V. Kulkarni U, et al. Among authors: balasundaram n. Cancer Med. 2020 Apr;9(8):2603-2610. doi: 10.1002/cam4.2883. Epub 2020 Feb 14. Cancer Med. 2020. PMID: 32059085 Free PMC article. Clinical Trial.
13 results